METHAZOLAMIDE TABLETS USP
25 mg and 50 mg
Methazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone.
Methazolamide tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Media Articles Related to Methazolamide
Glaucoma Drug Eyed as Novel Diabetes Treatment 'Archetype'
Source: Medscape Diabetes & Endocrinology Headlines [2014.08.21]
An old glaucoma drug, methazolamide, improved glucose control in a small study, probably due to a distinct mechanism that the manufacturer, Verva, hopes to pursue.
Medscape Medical News
Clinical Trials Related to Methazolamide
Rapid Acclimatization to Hypoxia at Altitude [Recruiting]
In low oxygen environments, such as altitude, some adults may become ill and suffer from
acute mountain sickness. Further, all adults will find that exercising becomes much more
difficult when compared with exercise at lower altitudes (e. g. sea-level). The purpose of
this investigation is to study the effects of two drugs that may help people adjust to
high-altitude quickly, prevent them from becoming ill and improve their exercise
performance. The drugs are Methazolamide and Aminophylline.
Improving Tumor Oxygenation in Cervical Cancer [Withdrawn]
The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with
ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are
affected adversely by acidic pH. These effects have primarily been attributed to the
presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to failure
of radiotherapy to cure certain malignancies has had a chequered history. However, in recent
years the evidence that hypoxia plays a central role in relative radioresistance has become
Since approximately two-thirds of all women suffering from cervical carcinoma receive
radiation as a component of their therapy, an enhanced understanding of the interactions
between hypoxia and radiation as a component of their therapy, an enhanced understanding of
the interactions between hypoxia and radiation resistance is critical to improving outcome
among those with cervical cancer.
Page last updated: 2014-08-21